Malarsjukhuset Eskilstuna — Clinical Trial Site

13 Registered trials

10 Currently recruiting

Organisation

Malarsjukhuset Eskilstuna

Location

Eskilstuna, Sweden

Identifier

ORG-100043147

Address

Kungsvagen 42, Tunafors, 633 49, Sweden

Departments

Delivery department, Mälarsjukhuset Eskilstuna, Kungsvagen 42, 63349 Eskilstuna
Department of oncology
Infektion, Entré 11, Björnströmsgatan 6, Mälarsjukhuset Eskilstuna
Infektionskliniken
Kliniska forskningsenheten (KFE), Onkologkliniken Sörmland
Medicinkliniken
N/A
Neurology
Oncology
Onkologkliniken
Reumatolgisk klinik, Region Sörmland

Clinical trials at this site (13)

Search interface

Tick-Borne Encephalitis (TBE) Remdesivir Efficacy Assessment Trial (TREAT) Pending

2025-523476-23-00 Tick-Borne Encephalitis (TBE) 4
The POWER trial: A randomised, two-armed open label phase 3 clinical trial on personalised dose optimisation with adjuvant tamoxifen therapy… Recruiting

2025-522240-40-00 Breast Cancer 5 2026-03-05
A Study to Learn About the Study Medicine Called PF-08046054/SGNPDL1V Versus Docetaxel in Adult Participants with Previously-treated Program… Recruiting

2025-521281-97-00 Non-Small Cell Lung Cancer (NSCLC) 5 2025-12-02
Pivmecillinam as oral step-down treatment for Escherichia coli febrile urinary tract infection versus standard of care; a randomized control… Recruiting

2023-503447-33-00 febrile Urinary Tract Infection (fUTI) 4 2025-11-13
Phase III trial of lomustine/temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagnosed MGMT promoter methylated gl… Recruiting

2023-506998-35-00 Glioblastoma 5 2025-01-08
Assessment of short immunotherapy after radical surgery of high-risk malignant melanoma Recruiting

2023-509994-22-00 cutaneous malignant melanoma 5 2024-11-15
A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pe… Recruiting

2023-503412-33-00 Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small 5 2024-03-29
A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer Recruiting

2022-501504-95-00 Non-metastatic HER2-positive Breast Cancer 4 2023-06-23
Alternative antibiotics to multidrug-resistant UTIs Recruiting

2024-513294-41-00 Urinary tract infection and/or bacteremia caused by ext 6 2023-04-17
SACK Recruiting

2022-501600-10-00 Atrial fibrillation and Chronic Kidney Disease stage 5 5 2023-02-07
OPTION – OutPatienT InductiON: Labour induction in an outpatient setting - a multicentre randomized controlled trial Recruiting

2023-507164-39-00 Induction of labour 6 2021-12-01
Efficacy, tolerability and preferences of per oral or subcutaneous methotrexate in patients with early rheumatoid arthritis – a randomised r… Ended

2024-512453-25-00 Rheumatoid arthritis 6 2022-04-28
A phase 3, randomised, double-blind, placebo-controlled, parallel-arm efficacy trial of Imatinib in acute ischaemic stroke Halted

2023-506178-11-00 Acute ischemic stroke 5 2025-11-11